The UPCI Flow Cytometry Facility moved to its new location at the Hillman Cancer Center Research Pavilion in September 2002. The new laboratory consists of a 200 ft 2 user laboratory (UserLab), and a 1000 ft 2 cell sorting laboratory. The Flow Cytometry Facility of the University of Pittsburgh Cancer Institute provides services to over 50 users within the UPCI and 20 non-UPCI users. These services fall into five categories: 1) Training users to operate the Facility's two user-dedicated analytical flow cytometers; 2) Performing high speed fluorescence activated cell sorting for investigators; 3) Insuring that the instruments in the facility are properly calibrated on a daily basis and advising users concerning the proper settings for their experiments; 4) Advising investigators on experimental design and data analysis and assisting in performance of complex multi-parameter experiments; and 5) Archiving all data produced by the facility. The current instrumentation at the UPCI Flow Cytometry Facility includes a Dako-Cytomation MoFLo high speed cell sorter, equipped with a CytoShield Biocontainment hood, a Dako-Cytomation CyAn 9-color high speed 9 color analyzer, and two Beckman Coulter XL 4-color analyzers. Despite the relocation to the Hillman Cancer Center, the usage of the flow cytometry facility has remained high, with cell sorting exclusive of setup time regularly exceeding 50% of absolute capacity (100 hours/month) and analytical cytometry exceeding 50% of business-hour capacity (160 hours/instrument/month). We anticipate that despite the loss of non-UPCI users resulting from the move, the recruitment of several new UPCI investigators and our continuing emphasis on education and training will more than make up for the loss of non-UPCI investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-19
Application #
7279240
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
19
Fiscal Year
2006
Total Cost
$113,120
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Song, Xinxin; Zhu, Shan; Chen, Pan et al. (2018) AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc- Activity. Curr Biol 28:2388-2399.e5
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Zhang, Jiliang; Zhang, Shaojuan; Liu, Yang et al. (2018) Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer. Photodiagnosis Photodyn Ther 24:185-191
Pascal, Laura E; Wang, Yao; Zhong, Mingming et al. (2018) EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer. Neoplasia 20:351-363
Robinson, Andria R; Yousefzadeh, Matthew J; Rozgaja, Tania A et al. (2018) Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging. Redox Biol 17:259-273
Overacre-Delgoffe, Abigail E; Vignali, Dario A A (2018) Treg Fragility: A Prerequisite for Effective Antitumor Immunity? Cancer Immunol Res 6:882-887
Nelson, Ashley M; Carew, Nolan T; Smith, Sage M et al. (2018) RNA Splicing in the Transition from B Cells to Antibody-Secreting Cells: The Influences of ELL2, Small Nuclear RNA, and Endoplasmic Reticulum Stress. J Immunol 201:3073-3083
Pore, Subrata K; Hahm, Eun-Ryeong; Latoche, Joseph D et al. (2018) Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate. Carcinogenesis 39:134-145
Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782
Weir, Mark C; Shu, Sherry T; Patel, Ravi K et al. (2018) Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo. ACS Chem Biol 13:1551-1559

Showing the most recent 10 out of 1187 publications